FOLD · AMICUS THERAPEUTICS, INC.
$14.49
+0.00 (+0.00%)
At close · Apr 27
Market Cap
$4.55B
Shares
314.00M
AMICUS THERAPEUTICS, INC. Earnings Call Transcripts
Every quarterly earnings call for AMICUS THERAPEUTICS, INC. (FOLD) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲18.5%
$78.72M
−$85.26M
'22 Q1
22-05-09
▲4.3%
$80.73M
−$62.16M
'22 Q2
22-08-04
▲2.7%
$81.69M
−$33.29M
'22 Q3
22-11-07
▲7.2%
$88.10M
−$55.87M
'22 Q4
23-03-01
▲9.6%
$86.27M
−$52.93M
'23 Q1
23-05-10
▲17.1%
$94.50M
−$43.23M
'23 Q2
23-08-08
▲26.7%
$103.50M
−$21.58M
'23 Q3
23-11-08
▲30.6%
$115.08M
−$33.84M
'23 Q4
24-02-28
▲28%
$110.40M
−$48.42M
'24 Q1
24-05-09
▲34%
$126.67M
−$15.70M
'24 Q2
24-08-08
▲36.7%
$141.52M
−$6.73M
'24 Q3
24-11-06
▲30.1%
$149.71M
$14.74M
'24 Q4
25-02-19
▲13.4%
$125.25M
−$21.69M
'25 Q1
25-05-01
▲22.1%
$154.69M
−$24.42M
'25 Q2
25-07-31
LATEST
▲19.5%
$169.06M
$17.31M
'25 Q3
25-11-04
Earnings call
FY26 · Q1
2026-05-04
BioMarin Pharmaceutical First Quarter 2026 Conference Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q3
2025-11-04
AMICUS THERAPEUTICS, INC. Q3 FY2025 Earnings Call
Confident tone
Pombiliti and Opfolda (Pompe) launch
Galafold commercial performance
Pipeline expansion / DMX-200 (FSGS)
Revenue
$169.06M
▲ 19.5% YoY Diluted EPS
$0.06
Gross margin
88.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
AMICUS THERAPEUTICS, INC. Q2 FY2025 Earnings Call
Confident tone
DMX-200 / FSGS pipeline (Dimerix partnership)
Travere FILSPARI AdCom read-through
Galafold (Fabry) commercial performance
Revenue
$154.69M
▲ 22.1% YoY Diluted EPS
$-0.08
Gross margin
90.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
AMICUS THERAPEUTICS, INC. Q1 FY2025 Earnings Call
Confident tone
Dimerix / DMX-200 partnership (FSGS)
Pombiliti + Opfolda (Pompe) launch
Galafold (Fabry) commercial performance
Revenue
$125.25M
▲ 13.4% YoY Diluted EPS
$-0.07
Gross margin
90.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-19
AMICUS THERAPEUTICS, INC. Q4 FY2024 Earnings Call
Confident tone
Pombiliti and Opfolda (Pom-Op) global launch
Galafold commercial performance and outlook
Geographic expansion and reimbursement
Revenue
$149.71M*
▲ 30.1% YoY Gross margin
90.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
AMICUS THERAPEUTICS, INC. Q3 FY2024 Earnings Call
Confident tone
Galafold commercial performance and revenue growth
Pombiliti and Opfolda global launch (Pompe disease)
Galafold IP litigation and Teva settlement
Revenue
$141.52M
▲ 36.7% YoY Diluted EPS
$-0.02
Gross margin
90.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
AMICUS THERAPEUTICS, INC. Q2 FY2024 Earnings Call
Confident tone
Pombiliti and Opfolda launch
Galafold commercial performance
Switch dynamics vs. Nexviazyme
Revenue
$126.67M
▲ 34% YoY Diluted EPS
$-0.05
Gross margin
91.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
AMICUS THERAPEUTICS, INC. Q1 FY2024 Earnings Call
Confident tone
Pombiliti and Opfolda launch
Galafold commercial performance
Pipeline and medical evidence (Fabry/Pompe studies)
Revenue
$110.40M
▲ 28% YoY Diluted EPS
$-0.16
Gross margin
87.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
AMICUS THERAPEUTICS, INC. Q4 FY2023 Earnings Call
Confident tone
Pombiliti and Opfolda launch
Galafold commercial performance
Financial position and profitability
Revenue
$115.08M*
▲ 30.6% YoY Gross margin
90.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
AMICUS THERAPEUTICS, INC. Q3 FY2023 Earnings Call
Revenue
$103.50M
▲ 26.7% YoY Diluted EPS
$-0.07
Gross margin
90.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
AMICUS THERAPEUTICS, INC. Q2 FY2023 Earnings Call
Revenue
$94.50M
▲ 17.1% YoY Diluted EPS
$-0.15
Gross margin
90.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
AMICUS THERAPEUTICS, INC. Q1 FY2023 Earnings Call
Revenue
$86.27M
▲ 9.6% YoY Diluted EPS
$-0.18
Gross margin
92.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
AMICUS THERAPEUTICS, INC. Q4 FY2022 Earnings Call
Revenue
$88.10M*
▲ 7.2% YoY Gross margin
89.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-07
AMICUS THERAPEUTICS, INC. Q3 FY2022 Earnings Call
Revenue
$81.69M
▲ 2.7% YoY Diluted EPS
$-0.12
Gross margin
83.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
AMICUS THERAPEUTICS, INC. Q2 FY2022 Earnings Call
Revenue
$80.73M
▲ 4.3% YoY Diluted EPS
$-0.21
Gross margin
89.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
AMICUS THERAPEUTICS, INC. Q1 FY2022 Earnings Call
Revenue
$78.72M
▲ 18.5% YoY Diluted EPS
$-0.30
Gross margin
90.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
AMICUS THERAPEUTICS, INC. Q4 FY2021 Earnings Call
Revenue
$82.15M*
▲ 16.4% YoY Gross margin
90.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
AMICUS THERAPEUTICS, INC. Q3 FY2021 Earnings Call
Revenue
$79.55M
▲ 18% YoY Diluted EPS
$-0.19
Gross margin
85.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
AMICUS THERAPEUTICS, INC. Q2 FY2021 Earnings Call
Revenue
$77.41M
▲ 24.2% YoY Diluted EPS
$-0.19
Gross margin
89.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
AMICUS THERAPEUTICS, INC. Q1 FY2021 Earnings Call
Revenue
$66.40M
▲ 9.7% YoY Diluted EPS
$-0.25
Gross margin
90.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
AMICUS THERAPEUTICS, INC. Q4 FY2020 Earnings Call
Revenue
$70.57M
▲ 27.6% YoY Gross margin
86.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
AMICUS THERAPEUTICS, INC. Q3 FY2020 Earnings Call
Revenue
$67.44M
▲ 38.3% YoY Diluted EPS
$-0.25
Gross margin
87.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
AMICUS THERAPEUTICS, INC. Q2 FY2020 Earnings Call
Revenue
$62.35M
▲ 41.3% YoY Diluted EPS
$-0.20
Gross margin
89.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
AMICUS THERAPEUTICS, INC. Q1 FY2020 Earnings Call
Revenue
$60.52M
▲ 77.8% YoY Gross margin
89.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-02
AMICUS THERAPEUTICS, INC. Q4 FY2019 Earnings Call
Revenue
$55.29M
▲ 69.4% YoY Gross margin
87.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–25 of 25 earnings calls